Considerations and caveats in anti-virulence drug development.
about
Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability.Using bacterial genomes and essential genes for the development of new antibiotics.Impact of Staphylococcus aureus regulatory mutations that modulate biofilm formation in the USA300 strain LAC on virulence in a murine bacteremia model.Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system.Salicylidene Acylhydrazides and Hydroxyquinolines Act as Inhibitors of Type Three Secretion Systems in Pseudomonas aeruginosa by Distinct Mechanisms.Host-derived fatty acids activate type VII secretion in Staphylococcus aureus.Nanoparticle-based local antimicrobial drug delivery.Structure-Function Relationship of Aminopeptidase P from Pseudomonas aeruginosa.A Coculture-Based Approach for Screening Campaigns Aimed at Identifying Novel Pseudomonas aeruginosa Quorum Sensing Inhibitors.A glimpse into the future - new therapeutic targets could transform the way we treat staphylococcal infections.Molecular Insights into Function and Competitive Inhibition of Pseudomonas aeruginosa Multiple Virulence Factor Regulator.Animal Models for Pseudomonas aeruginosa Quorum Sensing Studies.Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?in Chronic Lung Infections: How to Adapt Within the Host?Non-native autoinducer analogs capable of modulating the SdiA quorum sensing receptor in serovar Typhimurium
P2860
Q38756662-0F0823CA-9C76-44F0-96DB-A9E2DACB3318Q39035296-3968D40A-B8B6-466E-9721-B8518BDD0FA4Q40046083-23DD4D6F-5F0B-449F-B26C-21AA0CDD96A7Q40120435-C6219A48-F20F-40EF-AC63-AB33BB697C4DQ40257063-2925C208-30B5-460E-A84F-C9DABE2CD853Q41991541-41C16B72-E160-48B3-9581-286DBEB14650Q46223691-3DF2D7D8-7652-4FFF-A33F-BA85570E303EQ47233305-EEC65A56-BD6E-468E-8EF1-BA9859AA9210Q47411023-75DA28B7-4001-473D-BC9A-4C0D9BFF33B7Q47836772-23AC44BE-5B8F-4EC0-ACE2-5A709FE528E3Q50020529-C1CD380C-DF09-42BD-BBD4-3FA584579A42Q50053262-25BD212D-E795-453B-A13F-223AA3C7368AQ52655525-0105EB82-8E78-4D80-AA13-64C6D3C4AA47Q58580408-D68E3832-0790-4561-BD08-F9247953FEECQ58604936-87936793-883C-46EB-8678-435334A1D694
P2860
Considerations and caveats in anti-virulence drug development.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Considerations and caveats in anti-virulence drug development.
@en
type
label
Considerations and caveats in anti-virulence drug development.
@en
prefLabel
Considerations and caveats in anti-virulence drug development.
@en
P2093
P2860
P1476
Considerations and caveats in anti-virulence drug development.
@en
P2093
Alicia E Ballok
Damien Maura
Laurence G Rahme
P2860
P356
10.1016/J.MIB.2016.06.001
P577
2016-06-16T00:00:00Z